MMP-1(-1607G) polymorphism as a risk factor for fibrosis after pulmonary tuberculosis in Taiwan

Int J Tuberc Lung Dis. 2010 May;14(5):627-34.


Setting: Several matrix metalloproteinase (MMP) polymorphisms favouring the development of lung fibrosis after pulmonary tuberculosis (TB) have been described.

Objective: To investigate the association of MMP-1, MMP-9 and MMP-12 polymorphisms with the development of fibrosis in pulmonary TB.

Design: We studied 49 normal subjects and 98 TB patients. We analysed the association between MMP polymorphisms and clinical indices of lung fibrosis by serial chest radiography for 1 year after completion of treatment.

Results: The frequency of the MMP-1(-1607G) polymorphism was significantly higher in TB patients with moderate to advanced pulmonary fibrosis than in those with minimal to mild fibrosis. Having at least one -1607G MMP-1 polymorphism increased the risk of moderate and advanced fibrosis respectively by 5.04 (95%CI 1.25-20.30) and 9.87 (95%CI 2.39-40.88) fold. There was no association of MMP-9(-1562T) and MMP-12(Asn357Ser) polymorphisms with lung fibrosis. The production of MMP-1 from monocytes stimulated by interleukin-1 beta was increased in subjects with the 1G allele genotype compared to the 2G/2G genotype.

Conclusions: Patients with MMP-1(-1607G) polymorphism are more vulnerable to more extensive lung fibrosis 1 year after anti-tuberculosis treatment. This may be related to increased MMP-1 activity, leading to enhanced destruction of the matrix with subsequent fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antitubercular Agents / therapeutic use
  • Female
  • Fibrosis
  • Follow-Up Studies
  • Genetic Predisposition to Disease*
  • Humans
  • Lung / pathology*
  • Male
  • Matrix Metalloproteinase 1 / genetics*
  • Matrix Metalloproteinase 12 / genetics
  • Matrix Metalloproteinase 9 / genetics
  • Middle Aged
  • Polymorphism, Genetic
  • Prospective Studies
  • Risk Factors
  • Time Factors
  • Tuberculosis, Pulmonary / complications*
  • Tuberculosis, Pulmonary / drug therapy


  • Antitubercular Agents
  • Matrix Metalloproteinase 9
  • Matrix Metalloproteinase 12
  • Matrix Metalloproteinase 1